Danielle Horyniak1, Karla D Wagner2, Richard F Armenta3, Jazmine Cuevas-Mota4, Erik Hendrickson5, Richard S Garfein6. 1. Division of Global Public Health, Department of Medicine, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA; Behaviours and Health Risks Program, Burnet Institute, 85 Commercial Rd., Melbourne, VIC 3004, Australia; School of Public Health and Preventive Medicine, 99 Commercial Rd., Melbourne, VIC 3004, Australia. Electronic address: dhoryniak@ucsd.edu. 2. School of Community Health Sciences, University of Nevada Reno, 1664 N. Virginia St., Reno, NV 89557, USA. Electronic address: karlawagner@unr.edu. 3. Division of Epidemiology, Department of Family Medicine and Public Health, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA. Electronic address: rarmenta@ucsd.edu. 4. Division of Global Public Health, Department of Medicine, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA. Electronic address: jcuevasmota@ucsd.edu. 5. Division of Global Public Health, Department of Medicine, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA. Electronic address: ehendric@ucsd.edu. 6. Division of Global Public Health, Department of Medicine, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, USA. Electronic address: rgarfein@ucsd.edu.
Abstract
BACKGROUND: The prevalence of HIV and Hepatitis C Virus (HCV) are significantly lower among people who inject drugs (PWID) in San Diego, CA, USA compared with PWID in Tijuana, Mexico, located directly across the border. We investigated associations between cross-border injection drug use (IDU), HIV and HCV seroprevalence and engagement in injecting risk behaviours while on each side of the border. METHODS: Using baseline interviews and serologic testing data from STAHR II, a longitudinal cohort study of PWID in San Diego, bivariate and multivariable logistic regression analyses examined associations between recent (past six months) cross-border IDU and HIV and HCV antibody seropositivity, socio-demographics, drug use characteristics, and participants' connections to, and perceptions about Mexico. Chi-squared tests and McNemar tests examined associations between cross-border IDU and injecting risk behaviours. RESULTS: Of the 567 participants (93% U.S.-born, 73% male, median age 45 years), 86 (15%) reported recent cross-border IDU. Cross-border IDU was not associated with HIV (OR: 0.85, 95% CI: 0.37-1.95) or HCV seropositivity (OR: 1.01, 95% CI: 0.62-1.65). Age, identifying as Hispanic or Latino/a, and being concerned about risk of violence when travelling to Mexico were independently associated with decreased odds of recent cross-border IDU. Injecting cocaine at least weekly, having ever lived in Mexico and knowing PWID who reside in Mexico were associated with increased odds of recent cross-border IDU. PWID who reported cross-border IDU were significantly less likely to engage in receptive needle sharing, equipment sharing, and public injection while in Mexico compared with in San Diego (all p<0.001). CONCLUSION: Prevalence of HIV and HCV infection was similar among PWID who had and had not injected in Mexico, possibly due to practising safer injecting while in Mexico. Research is needed to elucidate contextual factors enabling U.S. PWID to inject safely while in Mexico.
BACKGROUND: The prevalence of HIV and Hepatitis C Virus (HCV) are significantly lower among people who inject drugs (PWID) in San Diego, CA, USA compared with PWID in Tijuana, Mexico, located directly across the border. We investigated associations between cross-border injection drug use (IDU), HIV and HCV seroprevalence and engagement in injecting risk behaviours while on each side of the border. METHODS: Using baseline interviews and serologic testing data from STAHR II, a longitudinal cohort study of PWID in San Diego, bivariate and multivariable logistic regression analyses examined associations between recent (past six months) cross-border IDU and HIV and HCV antibody seropositivity, socio-demographics, drug use characteristics, and participants' connections to, and perceptions about Mexico. Chi-squared tests and McNemar tests examined associations between cross-border IDU and injecting risk behaviours. RESULTS: Of the 567 participants (93% U.S.-born, 73% male, median age 45 years), 86 (15%) reported recent cross-border IDU. Cross-border IDU was not associated with HIV (OR: 0.85, 95% CI: 0.37-1.95) or HCV seropositivity (OR: 1.01, 95% CI: 0.62-1.65). Age, identifying as Hispanic or Latino/a, and being concerned about risk of violence when travelling to Mexico were independently associated with decreased odds of recent cross-border IDU. Injecting cocaine at least weekly, having ever lived in Mexico and knowing PWID who reside in Mexico were associated with increased odds of recent cross-border IDU. PWID who reported cross-border IDU were significantly less likely to engage in receptive needle sharing, equipment sharing, and public injection while in Mexico compared with in San Diego (all p<0.001). CONCLUSION: Prevalence of HIV and HCV infection was similar among PWID who had and had not injected in Mexico, possibly due to practising safer injecting while in Mexico. Research is needed to elucidate contextual factors enabling U.S. PWID to inject safely while in Mexico.
Authors: Tim Rhodes; Jo Kimber; Will Small; John Fitzgerald; Thomas Kerr; Matthew Hickman; Greg Holloway Journal: Addiction Date: 2006-10 Impact factor: 6.526
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: Robert A Gunn; Paula J Murray; Carolyn H Brennan; David B Callahan; Miriam J Alter; Harold S Margolis Journal: Sex Transm Dis Date: 2003-04 Impact factor: 2.830
Authors: Karla D Wagner; Matthew J Moynihan; Steffanie A Strathdee; Jazmine Cuevas-Mota; Maureen Clark; María Luisa Zúñiga; Tyson A Volkmann; Eyasu Teshale; Richard S Garfein Journal: J Ethn Subst Abuse Date: 2012 Impact factor: 1.507
Authors: M A Kramer; M G van Veen; E L M Op de Coul; R B Geskus; R A Coutinho; M J W van de Laar; M Prins Journal: Sex Transm Infect Date: 2008-07-24 Impact factor: 3.519
Authors: Steffanie A Strathdee; Remedios Lozada; Robin A Pollini; Kimberly C Brouwer; Andrea Mantsios; Daniela A Abramovitz; Tim Rhodes; Carl A Latkin; Oralia Loza; Jorge Alvelais; Carlos Magis-Rodriguez; Thomas L Patterson Journal: J Acquir Immune Defic Syndr Date: 2008-03-01 Impact factor: 3.731
Authors: Jason S Melo; Maria Luisa Mittal; Danielle Horyniak; Steffanie A Strathdee; Dan Werb Journal: Subst Use Misuse Date: 2018-01-24 Impact factor: 2.164
Authors: A Bórquez; R S Garfein; D Abramovitz; L Liu; L Beletsky; D Werb; S R Mehta; G Rangel; C Magis-Rodríguez; P González-Zúñiga; S A Strathdee Journal: J Immigr Minor Health Date: 2019-12
Authors: Angela R Bazzi; Chad J Valasek; Samantha A Streuli; Carlos F Vera; Alicia Harvey-Vera; Morgan M Philbin; Katie B Biello; Alexis M Roth; Steffanie A Strathdee; Heather A Pines Journal: AIDS Patient Care STDS Date: 2022-06-21 Impact factor: 5.944
Authors: Adriane Wynn; Samantha Tweeten; Eric McDonald; Wilma Wooten; Kimberley Lucas; Cassandra L Cyr; Maricris Hernandez; Franchesca Ramirez; Corey VanWormer; Scott Suckow; Christian B Ramers; Natasha K Martin Journal: PLoS One Date: 2021-06-09 Impact factor: 3.240
Authors: Hayley J Koslik; Jisha Joshua; Jazmine Cuevas-Mota; Daniel Goba; Eyal Oren; John E Alcaraz; Richard S Garfein Journal: Drug Alcohol Depend Date: 2020-07-02 Impact factor: 4.492